...diabetes and have the product in Phase III testing for heart failure. Astellas Pharma Inc., Kotobuki Pharmaceutical Co....

...product in Phase III testing as an adjuvant for liver cancer. Astellas Pharma Inc. and Kotobuki Pharmaceutical Co....

...Intelligence Modality Company Product Description Indication Phase of development Small molecules Astellas Pharma Inc. (Tokyo:4503); Kotobuki Pharmaceutical Co....

...Molecular subtype Phase Treatment Response rate (A) Overall survival (mos.) Astellas Pharma Inc. (Tokyo:4503) / Kotobuki Pharmaceutical Co....

...etoposide and intermediate-dose cytarabine (MEC); and fludarabine, cytarabine and G-CSF with idarubicin (FLAG-IDA). Astellas and Kotobuki...
...exclusive, worldwide rights to develop and commercialize the product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....

...Astellas and Merck's MSD K.K. subsidiary announced the partners along with Kotobuki launched Suglat ipragliflozin in...
...the indication in the country. Astellas will manufacture and sell Suglat and co-promote it with Kotobuki...
..."comprehensive consideration of intensified competition" for the diabetes product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....

...2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat with Kotobuki. Astellas, Kotobuki...
..."comprehensive consideration of intensified competition" for the diabetes product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....

...inhibitor approved for the indication in Japan. Astellas co-developed Suglat with Kotobuki Pharmaceutical Co. (Tokyo, Japan). Astellas, Kotobuki...

...Taisho Pharmaceutical Holdings Co. Ltd. , and ipragliflozin in Japan from Astellas Pharma Inc. and Kotobuki Pharmaceutical Co....
...Duesseldorf, Germany Geisinger Health System , Danville, Pa. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Kotobuki Pharmaceutical Co....

...Kotobuki granted Shionogi exclusive, worldwide rights to develop and commercialize cholesterol absorption inhibitor KT6-971 . Kotobuki...
...payment and is eligible for milestones and royalties. Shionogi declined to disclose financial details, while Kotobuki...
...dyslipidemia. Shionogi plans to start a Phase IIb trial by March 2013 for the indication. Kotobuki Pharmaceutical Co....